勘误：一线免疫检查点抑制剂治疗肺肉瘤样癌的疗效与安全性分析
Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
作者信息
Zeng Zhimin, Qian Xiaoying, Liu Fanrong, Wang Yong, Yuan Yong, Fang Chen, Zhang Xinwei, Yuan Shangkun, Chen Renfang, Yu Biao, Wang Tong, Yin Yan, Li Yong, Liu Anwen
机构信息
Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China.
出版信息
Front Immunol. 2023 Sep 6;14:1269596. doi: 10.3389/fimmu.2023.1269596. eCollection 2023.
Abstract
[This corrects the article DOI: 10.3389/fimmu.2022.956982.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fimmu.2022.956982。]
相似文献
1
Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.勘误：一线免疫检查点抑制剂治疗肺肉瘤样癌的疗效与安全性分析
Front Immunol. 2023 Sep 6;14:1269596. doi: 10.3389/fimmu.2023.1269596. eCollection 2023.
2
The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.一线免疫检查点抑制剂在肺肉瘤样癌中的疗效和安全性分析。
Front Immunol. 2022 Oct 31;13:956982. doi: 10.3389/fimmu.2022.956982. eCollection 2022.
3
Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.病例报告：肺肉瘤样癌合并TP53突变经替雷利珠单抗联合安罗替尼成功治疗——一例病例报告
Front Genet. 2022 Jul 22;13:949989. doi: 10.3389/fgene.2022.949989. eCollection 2022.
4
Case report: Fatal hemoptysis after effective treatment with tislelizumab and anlotinib in pulmonary sarcomatoid carcinoma.病例报告：替雷利珠单抗联合安罗替尼有效治疗肺肉瘤样癌后出现致命性咯血
Front Oncol. 2024 Sep 30;14:1445358. doi: 10.3389/fonc.2024.1445358. eCollection 2024.
5
Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation.病例报告：替雷利珠单抗联合安罗替尼一线治疗伴肉瘤样癌分化的转移性肾盂尿路上皮癌的显著疗效
Front Oncol. 2022 Oct 18;12:969106. doi: 10.3389/fonc.2022.969106. eCollection 2022.
6
Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.安罗替尼联合化疗及免疫治疗晚期肺肉瘤样癌：一例报告及文献复习
Ann Transl Med. 2022 Sep;10(18):1030. doi: 10.21037/atm-22-4312.
7
Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review.抗 PD-1 抗体卡瑞利珠单抗联合多柔比星在肺肉瘤样癌中显示出持久的缓解：病例报告和文献复习。
J Clin Pharm Ther. 2020 Dec;45(6):1489-1496. doi: 10.1111/jcpt.13234. Epub 2020 Aug 10.
8
Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report.使用 PD-1 抑制剂替雷利珠单抗治疗晚期肺肉瘤样癌：一例报告。
Thorac Cancer. 2022 Feb;13(3):502-505. doi: 10.1111/1759-7714.14290. Epub 2021 Dec 24.
9
Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.病例报告：安罗替尼联合替雷利珠单抗有效治疗PD-L1阴性晚期膀胱癌：两例报告
Front Oncol. 2023 Apr 14;13:1164368. doi: 10.3389/fonc.2023.1164368. eCollection 2023.
10
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features.一线免疫检查点抑制剂治疗具有肉瘤样特征的晚期或转移性肾细胞癌。
Cancer Treat Rev. 2022 Apr;105:102374. doi: 10.1016/j.ctrv.2022.102374. Epub 2022 Mar 10.
引用本文的文献
1
Camrelizumab combined with chemotherapy for stage IV pulmonary sarcomatoid cancer with pancreatic metastases.卡瑞利珠单抗联合化疗治疗伴有胰腺转移的IV期肺肉瘤样癌。
Respir Med Case Rep. 2024 Aug 29;51:102101. doi: 10.1016/j.rmcr.2024.102101. eCollection 2024.
Zotero 插件